6/29/23, 11:57 PM SURMOUNT-1 (mid-dose) Pathway Feedback Search Clinical Topics Home Studies SURMOUNT 1 (mid-dose) SURMOUNT 1 (mid-dose) Disease Obesity Trial question What is the role of a mid-dose of tirzepatide in adults with obesity? Study design Multi-center Double blinded RCT Population Characteristics of study participants 67.0% female N = 1279 33.0% male 1279 patients (863 female, 416 male) Inclusion criteria: adults with a BMI > 30, or > 27 and at least one weight-related complication, excluding diabetes Key exclusion criteria: diabetes; a change in body weight > 5 kg within 90 days before screening; previous or planned surgical treatment for obesity; treatment with a medication that promotes weight loss within 90 days before screening Interventions N=636 mid-dose of tirzepatide (a subcutaneous dose of 10 mg once weekly for 72 weeks) N=643 placebo (matching placebo once-weekly) Primary outcome https://web.pathway.md/studies/reclUVk0iZdXENScs 1/2 6/29/23, 11:57 PM SURMOUNT-1 (mid-dose) Pathway Weight reduction at week 72 19.5 % 19.5 14.6 % 9.8 % Significant increase 4.9 % NNT = 6 3.1 0.0 % Mid-dose of tirzepatide Placebo Significant increase in weight reduction at week 72 (19.5% vs. 3.1%; AD 16.4%, 95% CI 14.8 to 17.9) Secondary outcomes Significant increase in the percentage of patients achieving a weight reduction of 5% at week 72 (88.9% vs. 34.5%; AD 54.4%, 95% CI 22.12 to 86.68) Significant increase in the percentage of patients achieving a weight reduction of 10% at week 72 (78.1% vs. 18.8%; AD 59.3%, 95% CI 24.11 to 94.49) Significant increase in reduction in waist circumference (17.7 cm vs. 4 cm; AD 13.8 cm, 95% CI 12.3 to 15.2) Safety outcomes No significant difference in serious adverse events. Conclusion In adults with a BMI > 30, or > 27 and at least one weight-related complication, excluding diabetes, mid-dose of tirzepatide was superior to placebo with respect to weight reduction at week 72. Reference Ania M Jastreboff, Louis J Aronne, Nadia N Ahmad et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. Open reference URL https://web.pathway.md/studies/reclUVk0iZdXENScs 2/2